XERS: Xeris Biopharma Holdings, Inc. Stock

by  •  • Comments Off on XERS: Xeris Biopharma Holdings, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 275.75
Enterprise Value ($M) 399.23
Book Value ($M) -6.78
Book Value / Share -0.05
Price / Book -40.66
NCAV ($M) -173.12
NCAV / Share -1.17
Price / NCAV -1.59

Profitability (mra)
Return on Invested Capital (ROIC) -0.28
Return on Assets (ROA) -0.19
Return on Equity (ROE) -2.07

Liquidity (mrq)
Quick Ratio 1.23
Current Ratio 1.64

Balance Sheet (mrq) ($M)
Current Assets 156.26
Assets 322.60
Liabilities 329.38
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 163.91
Operating Income -44.01
Net Income -62.26
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -47.02
Cash from Investing -6.00
Cash from Financing -1.61

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Stonepine Capital Management, LLC 4.30 -46.97
02-13 13G Vanguard Group Inc 5.13
01-26 13G BlackRock Inc. 7.20 494.44

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-06 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PUR
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION R
2023-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT
2023-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPOR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 216,281 1,130,222 19.14
2024-05-02 261,380 319,738 81.75
2024-05-01 253,673 478,691 52.99
2024-04-30 187,654 236,833 79.23

(click for more detail)

Similar Companies
VTYX – Ventyx Biosciences, Inc. VYGR – Voyager Therapeutics, Inc.
XBIT – XBiotech Inc. XLO – Xilio Therapeutics, Inc.
YMAB – Y-mAbs Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io